Canadian Rapid Treatment Centre of Excellence

Canadian Rapid Treatment Centre of Excellence, commonly known as CRTCE and now branded as Braxia Health, is a Canadian specialty mental health clinic network focused on rapid-acting psychedelic and ketamine-based treatments for patients with difficult-to-treat mood disorders. The organization was established in 2018 and provides physician-referred outpatient care, emphasizing treatment-resistant depression and bipolar depression, with some case-by-case assessment of PTSD and OCD. Its service offering has included intravenous ketamine, intranasal esketamine historically, and more recently IV and oral ketamine-based psychedelic therapy delivered under supervised clinical protocols. In addition to clinical care, CRTCE has described its sites as multidisciplinary outpatient clinical research facilities. The business is best characterized as a commercial healthcare services provider rather than a drug-development biotech company.